RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young B. Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt, Jennifer R. Diamond
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-11-01
coleção:	BMC Cancer
Assuntos:	RX-5902 Triple-negative breast cancer p68 β-Catenin PD-1 inhibitor Immunotherapy
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-020-07500-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!